ArticlePloS one2017
Fatigue in patients with neuromyelitis optica spectrum disorder and its impact on quality of life.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Exploring core symptoms and symptom clusters among patients with neuromyelitis optica spectrum disorder: A network analysis.International journal of nursing sciences · 2025Article
- Sex hormones and neuromyelitis optica spectrum disorder: a bidirectional Mendelian randomization study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Article
- Usefulness of the MFIS-K, FSS, and FACIT-F Fatigue Scales in Korean Patients With MS, NMOSD, and MOGAD.Journal of clinical neurology (Seoul, Korea) · 2024Article
- Sleep and neuroimmunology: a narrative review.Encephalitis (Seoul, Korea) · 2024Article
- Effect of ginseng on fatigue related to neuromyelitis optica spectrum disorder: A double-blinded randomized controlled clinical trial.Caspian journal of internal medicine · 2024Article
- Article
- The association between cognition and gait disturbance in central nervous system demyelinating disorder with mild disability.BMC neurology · 2023Article
- Impact of dysautonomic symptom burden on the quality of life in Neuromyelitis optica spectrum disorder patients.BMC neurology · 2023Article
- Shared imaging markers of fatigue across multiple sclerosis, aquaporin-4 antibody neuromyelitis optica spectrum disorder and MOG antibody disease.Brain communications · 2023Article
- NMOSD-Diagnostic Dilemmas Leading towards Final Diagnosis.Brain sciences · 2022Article
- Brain structural and functional connectivity alterations are associated with fatigue in neuromyelitis optica spectrum disorder.BMC neurology · 2022Article
- Symptomatic and restorative therapies in neuromyelitis optica spectrum disorders.Journal of neurology · 2022Review
- Association of subcortical structural shapes with fatigue in neuromyelitis optica spectrum disorder.Scientific reports · 2022Article
- The patient journey with NMOSD: From initial diagnosis to chronic condition.Frontiers in neurology · 2022Article
- Early Treatment Initiation With Oral Prednisolone for Relapse Prevention Alleviates Depression and Fatigue in Aquaporin-4-PositiveFrontiers in neurology · 2021Article
- Cognitive impairment in NMOSD-More questions than answers.Brain and behavior · 2020Review
- Neuromyelitis optica and myotonic dystrophy type 2: a rare association with diagnostic implications.Journal of neurology · 2020Article
- Factors associated with fatigue in CNS inflammatory diseases with AQP4 and MOG antibodies.Annals of clinical and translational neurology · 2020Article
- Cognitive Impairment in Neuromyelitis Optica Spectrum Disorders: A Review of Clinical and Neuroradiological Features.Frontiers in neurology · 2019Review
- Quality of life and its influencing factors in patients with neuromyelitis optica spectrum disorder.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fatigue is a prevalent symptom and major burden in neuroimmunological diseases. In neuromyelitis optica spectrum disorder (NMOSD), a severe autoimmune central nervous system (CNS) inflammatory disease with autoantibodies reactive to aquaporin-4, there are few reports about fatigue and quality of life (QOL). We aimed to evaluate the severity of fatigue and its relationship with QOL in patients with NMOSD. We prospectively studied patients with NMOSD who were in remission and seropositive for anti-aquaporin-4 antibody, and they were divided into 2 groups based on the presence of fatigue assessed using the Functional Assessment of Chronic Illness Therapy-fatigue score. Sleep quality, depression, pain, and QOL were also evaluated. A total of 35 patients were enrolled (mean age, 46.5 ± 14.1 years; female: male = 29:6), and the median Expanded Disability Status Scale (EDSS) score was 2.0 (range, 0 to 8.0). The patients with fatigue (N = 25, 71.4%) had poorer sleep quality and more severe depression than those without fatigue (p = 0.009 and p = 0.001). Both the physical and mental QOL scores were lower in patients with fatigue than in those without fatigue (p = 0.033 and p = 0.004). Multiple linear regression analyses showed that the degree of fatigue with EDSS score and pain were independent predictors of physical aspects of QOL (B = 0.382, p = 0.001), whereas depression was the only predictor of the mental components of QOL (B = -0.845, p = <0.001). Fatigue is a common symptom and an important predictor of QOL in patients with NMOSD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.